MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.235
+0.005
+0.41%
Opening 14:22 06/17 EDT
OPEN
1.220
PREV CLOSE
1.230
HIGH
1.240
LOW
1.210
VOLUME
450.00K
TURNOVER
--
52 WEEK HIGH
6.14
52 WEEK LOW
0.9710
MARKET CAP
61.79M
P/E (TTM)
-0.6899
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 06/09 20:44
64 Biggest Movers From Friday
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring dev...
Benzinga · 06/07 09:09
Will Idera Pharmaceuticals (NASDAQ:IDRA) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 06/05 09:59
40 Stocks Moving In Friday's Mid-Day Session
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday.
Benzinga · 06/04 16:04
DOCU, CLNE, KNDI and SENS among premarket gainers
Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories...
Seekingalpha · 06/04 12:21
Idera Pharma rises as insider buys shares
Idera Pharmaceutical (IDRA) has added ~7.6% in the post-market after the company issued a regulatory filing to disclose an insider purchase by Michael Dougherty, the chair of the Board.On a transaction dated June 01, Mr.
Seekingalpha · 06/03 20:49
Insider Trends: 90-Day Buying Trend Extended with Insider Purchase of Idera Pharmaceuticals Stock
MT Newswires · 06/03 16:15
The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation
Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.
Benzinga · 05/23 14:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDRA. Analyze the recent business situations of Idera Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDRA stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 94
Institutional Holdings: 12.37M
% Owned: 24.72%
Shares Outstanding: 50.03M
TypeInstitutionsShares
Increased
20
2.35M
New
17
2.35M
Decreased
11
3.57M
Sold Out
14
820.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.02%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
Non-Executive Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Vincent Milano
Chief Financial Officer/Senior Vice President
John Kirby
Chief Operating Officer/Senior Vice President
Daniel Soland
Senior Vice President/General Counsel/Secretary
Bryant Lim
Independent Director
Cristina Csimma
Independent Director
Michael Dougherty
Independent Director
Mark Goldberg
Independent Director
Maxine Gowen
Independent Director
Carol Schafer
No Data
About IDRA
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.